Gadolinium toxicity
Knowledge gaps, prioritization of research roadmap

Val M. Runge, MD
University Hospital Bern
Switzerland
Conflicts of Interest

Has been involved in gadolinium-related research since 1982; in the current year, 2018, is principal investigator for two small research grants to his department in Bern Switzerland, <= 10,000 Euro each, one from Guerbet and one from Bayer; will also receive honoraria in 2018 for presentations at the CMR meeting in Barcelona and the ECR meeting in Vienna during industry-sponsored (Bayer) symposia.
Discussion and Knowledge Gaps

• need to re-evaluate aspects of nonclinical studies
  – Exposure/toxicity relationship of GBCAs particularly for chronic exposure
  – CNS safety in juvenile and adult animals
• filling the gaps from nonclinical perspectives
  – Animal models: species; prenatal, juvenile, adult
  – Study protocol standardization: dose, dose multiples, dose timing, dose frequency, observational batteries, timing of evaluations, assay methodologies (Gd)
Discussion and Knowledge Gaps 2

- dissociation of Gd may result in unknown number of intermediate metabolites, the toxicology of which has not been evaluated
- could there be any resultant organo-metallic compounds formed?
- what concentration of Gd deposits of what diameter(s) result in a certain observed MRI signal?
Discussion and Knowledge Gaps 3

• how does one define gadolinium toxicity?
• are symptoms of gadolinium toxicity reproducible?
• is dechelation required to produce symptoms?
• what are the stabilities of the gadolinium chelates at lysosomal pH?